AMT

Next Generation Waters - Nuu

...ill be attending the DPI Food Show in Chicago, Illinois on July 8, 2009. Nuu waters will be represented by Consumer Product Management, Inc. and amt Sales and Marketing. ...

DFG establishes nine new collaborative research centers

...TH); Ruprecht-Karls University Heidelberg; University of Duisburg-Essen and the Landschaftsverband Rheinland (Rhineland Regional Council); Rheinisches amt fr Bodendenkmalpflege, Bonn (Rhineland Office for the Preservation of Archaeological Sites); Neanderthal Museum, Mettmann) In contrast to the exten...

Meditor Pharmaceuticals (North American) Ltd. announces the closing of a merger agreement with American Medical Technologies, Inc.

...rry Skolnik, President of MEDITOR and Dr. Boris Farber, CEO and Chairman of amt are continuing to develop relationships with market makers in Europe to help create additional investor awareness of Meditor and amt on the Frankfurt and Berlin Exchanges. The company's first stop on its in...

InfoLogix Announces First Quarter 2008 Financial Results

...Acquisitions: Focus on potential acquisitions, opportunities as well as continue the integration of the Healthcare Informatics Associates and amt Systems acquisitions. -- Organic Revenue Growth: Continue to capitalize on the newly trained and fully capable sales force in order to increase...

Tax Planning Ideas: Sound Strategies Protect Wealth, Advises Whitnell & Co.

..., which can be up to 50% of their estate. Today's complicated tax laws offer many avenues for protecting wealth. High net worth people can avoid the amt by forecasting predicted income -- including their salary, stock options, and sales of assets -- and balancing those items with strategic charitable g...

Amsterdam Molecular Therapeutics Initiates Program for Late Stage Liver Cirrhosis and Reports Strong Progress in AMT-011 With Trial Fully Recruited and European and US Submission On Track for First Half of 2008

... The agreement stems from the exclusive license to amt from Digna Biotech to commercialize all gene thera...g, but also comes at a very high cost for society. amt is fully dedicated and equipped to add this new pr...2008. Conference call and webcast presentation amt will conduct a conference call open to the public ...

Bracco Announces Initiative to Save Children in China at 2007 Annual Meeting of CGI

... OTC pharmaceutical products and healthcare services in Italy, as well as Advanced Medical Technology systems on a world wide basis through the Bracco amt companies, ACIST Medical Systems, based in Minneapolis, and Volume Interactions of Singapore. Bracco is present in approximately 80 countries both dir...

'Compromise' SCHIP Deal Substitutes Ideology for Common Sense

...promise" bill will shift two million children who already have insurance to a government-run program. Provides Coverage for Families Paying amt -- Expands SCHIP eligibility up to 300% of federal poverty level and grandfathers States with higher eligibility levels. Under the Senate pro...

AMT in Medical Technology

Glybera(TM) Shows Long-Term Health Benefits

...t the treatment is well-tolerated and safe. amt has developed Glybera as a treatment for patients ... About Amsterdam Molecular Therapeutics amt has a unique production platform that circumvents ...phan) diseases that are caused by one faulty gene. amt currently has a product pipeline with nine product...

AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria

...). Orphan Drug Designation for AIP entitles amt to ten year market exclusivity in Europe following...ptoms and consequences of acute porphyric attacks. amt has demonstrated that its product, AMT-021, result... About Amsterdam Molecular Therapeutics amt has a unique gene therapy platform that to date ap...

AMT: Glybera(R) Lowers Pancreatitis Incidence Significantly

...t the treatment is well-tolerated and safe. amt has developed Glybera as an effective treatment fo... About Amsterdam Molecular Therapeutics amt has a unique gene therapy platform that to date ap...phan) diseases that are caused by one faulty gene. amt currently has a product pipeline with seven produc...

AMT Intends to Incorporate Additional Data to its Marketing Authorization Dossier for Glybera(R)

...uropean Medicines Agency (EMEA) and Health Canada, amt has decided to expand the clinical experience and ...dy to be done with existing financial resources. amt has developed Glybera(R) as a cure for patients wi...mptoms. About Amsterdam Molecular Therapeutics amt has a unique gene therapy platform that to date ap...

AMT Obtains License to Amgen's GDNF Gene to Develop Treatment for Parkinson's Disease with AMT's Proprietary Gene Therapy Platform

... debilitating disease," said Ronald Lorijn, CEO of amt "We believe our gene therapy approach could be an ...y for the development and survival of nerve cells. amt will combine this gene with its own proprietary te...ndidate for the treatment of Parkinson's disease.. amt believes that its gene-delivery platform may poten...

AMT Prepares for Submission of Marketing Authorization Dossier for AMT-011 (Glybera(R))

... EMEA not later than the fourth quarter of 2008. amt has developed AMT-011 as a cure for patients with ...o plan. About Amsterdam Molecular Therapeutics amt has a unique gene therapy platform that to date ap...phan) diseases that are caused by one faulty gene. amt currently has a product pipeline with seven produc...

AMT Announces Positive Interim Clinical Data on its Lead Product AMT-011

...era(R). About Amsterdam Molecular Therapeutics amt has a unique gene therapy platform that to date ap...phan) diseases that are caused by one faulty gene. amt currently has a product pipeline with six products...overnmental and regulatory approvals and consents. amt expressly disclaims any intent or obligation to up...

Amsterdam Molecular Therapeutics BV to present preclinical proof-of-concept data on its gene therapy AMT-020 to treat acute intermittent porphyria

...erm therapeutic protein expression in non-human primates." -ENDS- About amt Amsterdam Molecular Therapeutics BV (AMT) is a gene therapy company found... by scientists of the University of Amsterdam Medical Center (AMC) in 1998. amt focuses on the development of gene-based therapies for orphan metabolic and...

AMT Presents Positive Results of Phase I/II Study with Lead Product at Annual Meeting of American Society of Gene Therapy

...phan) diseases that are caused by one faulty gene. amt currently has a product pipeline with six products... is limited and not harmful to humans. About amt Amsterdam Molecular Therapeutics BV (AMT) is a g...versity of Amsterdam Medical Center (AMC) in 1998. amt focuses on the development of gene-based therapies...

AMT in Medical Products

AMT

Description:... Established in 1939, amt has become one of the nations premier certificatio...actitioners and other allied health professionals. amt provides certification for Medical Technologists, ...d Dental Assistants and Allied Health Instructors. amt has a continuing education program along with a ho...
Company:American Medical Technologists (AMT)

AMT in Biological Technology

AMT Starts Preregistration Trial for Glybera(TM)

...unexpected side-effects have been observed. amt will include the data from the new trial in the Ma... About Amsterdam Molecular Therapeutics amt has a unique gene therapy platform that to date ap...ose that are caused by one faulty gene. Currently, amt has a product pipeline with nine products at diffe...

Amsterdam Molecular Therapeutics Reports Full Year Results 2008

...UR 14.9 million for 2007. As of December 31, 2008, amt had cash and cash equivalents of EUR 34.2 million,...RO 17.2 million which is in line with the guidance amt has given for 2008. "Despite the setback in... Conference call and webcast presentation amt will conduct a conference call open to the public ...

AMT to Release Full Year 2008 Results on February 24, 2009

...ernet, visit the investor relations portion of the amt website at http://www.amtbiopharma.com . Please g... About Amsterdam Molecular Therapeutics amt has a unique gene therapy platform that to date ap...rare) diseases that are caused by one faulty gene. amt currently has a product pipeline with nine product...

AMT CEO Ronald Lorijn Steps Down

...basis. Since Ronald Lorijn started in 2005, amt changed from a small, one-product company into a l... Sander van Deventer: "I look forward to guiding amt at this important stage with the clinical trial fo... About Amsterdam Molecular Therapeutics amt has a unique gene therapy platform that to date ap...

Amsterdam Molecular Therapeutics Reports Half Year Results 2008

...t half of 2008. During the first half of this year amt has made substantial progress in the development o... AMT. Conference call and webcast presentation amt will conduct a conference call open to the public ...e call. About Amsterdam Molecular Therapeutics amt has a unique gene therapy platform that to date ap...

AMT to Release Half Year 2008 Results on August 13, 2008

...nce call live via the internet, visit the investor relations portion of the amt website at http://www.amtbiopharma.com . Please go to the website 15 minut...ll the necessary audio software. About Amsterdam Molecular Therapeutics amt has a unique gene therapy platform that to date appears to circumvent many ...

AMT Appoints Director Global Marketing and Sales

...'s lead product Glybera(R). Mrs. De Wal comes to amt from Genzyme, which she joined in 2003. She was a ...n 1986. About Amsterdam Molecular Therapeutics amt has a unique gene therapy platform that to date ap...overnmental and regulatory approvals and consents. amt expressly disclaims any intent or obligation to up...

AMT Starts Collaboration With St. Jude Children's Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy

...herapy treatment for Hemophilia B. Under the deal, amt will receive the exclusive commercial rights to th...h leading research institute Under the agreement amt will sponsor research in Hemophilia B at St. Jude. Ronald Lorijn, CEO of amt said: "The importance of this collaboration with r...

AMT Makes Important Advance in the Development of its Gene Therapy for Hemophilia B -Company Accesses Technology to Prevent Immune Response

... therapy for Hemophilia B. This technology enables amt to accelerate the development of AMT-060 (AMT's AA...duces Factor IX and thereby repair blood clotting. amt will use the TIGET technology to prevent an immune...group of professor Naldini Ronald Lorijn, CEO of amt said: "We are very excited to have licenced this g...

AMT Announces Presentations During the 11th Annual Meeting of the ASGT

...May 29. About Amsterdam Molecular Therapeutics amt has a unique gene therapy platform that to date ap...phan) diseases that are caused by one faulty gene. amt currently has a product pipeline with six products...overnmental and regulatory approvals and consents. amt expressly disclaims any intent or obligation to up...